open access

Vol 3, No 2 (2014)
Original articles (submitted)
Published online: 2014-05-14
Get Citation

Clinical and epidemiological evaluation of type 2 diabetic patients treated with extended-release metformin. EpiDiaMet Study

Krysztof Strojek, Dominika Rokicka, Aleksandra Szymborska-Kajanek, Marta Wróbel
Diabetologia Kliniczna 2014;3(2):46-50.

open access

Vol 3, No 2 (2014)
Original articles (submitted)
Published online: 2014-05-14

Abstract

Introduction. Optimal metabolic control is crucial for the prevention of diabetic complications, considered one of the most important problems of current medi­cine. Aims of the work: 1. epidemiological assessment of type 2 diabetic patients treated with extended­-release metformin; 2. assessment of parameters for diabetes control after a 3-month observation, during which physicians treated patients according to local practice; 3. comparison with other epidemiological analyses, ARETAEUS1 and OPTIMO completed in Poland in the last years. Material and methods. A total of 1767 type 2 dia­betic patients with poor metabolic control, treated with extended-release metformin, who presented in a general practitioner office for routine control visit (15 consecutive patients) were included. Mean age (± SD) was 59 ± 11 years, mean diabetes duration 5 ± 7 years. Data on metabolic control and diabetic complications were collected at baseline and after 3 months, using a specific questionnaire. Data were compared to ARETAEUS1 and OPTIMO analyses. Results. After 3 months observation glycated hemoglo­bin decreased from 7.58 ± 3.14 to 7.38 ± 8.49 (p < 0.02). Blood pressure (systolic/diastolic) decreased from 138 ± 18/85 ± 22 to 130 ± 34/80 ± 10 mm Hg (p < 0.001). Statistically significant (p < 0.001) improve­ments in lipids parameters were also recorded: baseline mean (± SD) total cholesterol level decreased: before 5.67 ± 2.24 and after 5.19 ± 3.42 mmol/l; low-density lipoprotein (LDL) cholesterol level decreased: before 3.47 ± 1.79 and after 3.11 ± 2.00 mmol/l; high-density lipoprotein (HDL) cholesterol level increased from 1.23 ± 0.38 to 1.30 ± 0.36 mmol/l. At baseline 14% of patients received a high dose (2000 mg or higher) of extended release metformin and after 3 months of observation the percentage rose to 34%. Conclusions. The reported EpiDiaMet study, conducted in type 2 diabetic patients with short duration of diabetes, treated with extended-release metformin indicates the need for treatment intensification and maximization of metformin doses.

Abstract

Introduction. Optimal metabolic control is crucial for the prevention of diabetic complications, considered one of the most important problems of current medi­cine. Aims of the work: 1. epidemiological assessment of type 2 diabetic patients treated with extended­-release metformin; 2. assessment of parameters for diabetes control after a 3-month observation, during which physicians treated patients according to local practice; 3. comparison with other epidemiological analyses, ARETAEUS1 and OPTIMO completed in Poland in the last years. Material and methods. A total of 1767 type 2 dia­betic patients with poor metabolic control, treated with extended-release metformin, who presented in a general practitioner office for routine control visit (15 consecutive patients) were included. Mean age (± SD) was 59 ± 11 years, mean diabetes duration 5 ± 7 years. Data on metabolic control and diabetic complications were collected at baseline and after 3 months, using a specific questionnaire. Data were compared to ARETAEUS1 and OPTIMO analyses. Results. After 3 months observation glycated hemoglo­bin decreased from 7.58 ± 3.14 to 7.38 ± 8.49 (p < 0.02). Blood pressure (systolic/diastolic) decreased from 138 ± 18/85 ± 22 to 130 ± 34/80 ± 10 mm Hg (p < 0.001). Statistically significant (p < 0.001) improve­ments in lipids parameters were also recorded: baseline mean (± SD) total cholesterol level decreased: before 5.67 ± 2.24 and after 5.19 ± 3.42 mmol/l; low-density lipoprotein (LDL) cholesterol level decreased: before 3.47 ± 1.79 and after 3.11 ± 2.00 mmol/l; high-density lipoprotein (HDL) cholesterol level increased from 1.23 ± 0.38 to 1.30 ± 0.36 mmol/l. At baseline 14% of patients received a high dose (2000 mg or higher) of extended release metformin and after 3 months of observation the percentage rose to 34%. Conclusions. The reported EpiDiaMet study, conducted in type 2 diabetic patients with short duration of diabetes, treated with extended-release metformin indicates the need for treatment intensification and maximization of metformin doses.

Get Citation

Keywords

type 2 diabetes, metabolic control, extended-release metformin (XR)

About this article
Title

Clinical and epidemiological evaluation of type 2 diabetic patients treated with extended-release metformin. EpiDiaMet Study

Journal

Clinical Diabetology

Issue

Vol 3, No 2 (2014)

Pages

46-50

Published online

2014-05-14

Bibliographic record

Diabetologia Kliniczna 2014;3(2):46-50.

Keywords

type 2 diabetes
metabolic control
extended-release metformin (XR)

Authors

Krysztof Strojek
Dominika Rokicka
Aleksandra Szymborska-Kajanek
Marta Wróbel

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl